ArticleBMC infectious diseases2008
Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003.
Article in BMC infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World.BioMed research international · 2019Trial
- Pulmonary tuberculosis complicated by pneumothorax, and acute respiratory distress syndrome (ARDS) in the settings of advanced HIV disease: A case report.Journal of clinical tuberculosis and other mycobacterial diseases · 2023Article
- Spatiotemporal Clusters and Trends of Pneumocystis Pneumonia in Korea.The Korean journal of parasitology · 2022Article
- Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations.International journal of environmental research and public health · 2022Article
- Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on SevereFrontiers in medicine · 2022Article
- Pneumocystis in metastatic lung cancer, a pragmatic approach in support of prophylaxis.BMJ case reports · 2021Article
- Tension pneumomediastinum: A literal form of chest tightness.Journal of the Intensive Care Society · 2017Article
- Observational
- Neither classical nor alternative macrophage activation is required for Pneumocystis clearance during immune reconstitution inflammatory syndrome.Infection and immunity · 2015Article
- Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections.Mucosal immunology · 2014Review
- Article
- STAT4-dependent and -independent Th2 responses correlate with protective immunity against lung infection with Pneumocystis murina.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.Emerging infectious diseases · 2013Article
- Colonization by Pneumocystis jirovecii and its role in disease.Clinical microbiology reviews · 2012Review
- The state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.Eukaryotic cell · 2012Article
- Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.Proceedings of the American Thoracic Society · 2011Review
- HIV-associated Pneumocystis pneumonia.Proceedings of the American Thoracic Society · 2011Review
- IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Clinical and translational research in pneumocystis and pneumocystis pneumonia.Parasite (Paris, France) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPneumocystis pneumonia (PCP) remains a leading cause of morbidity and mortality in HIV-infected persons. Epidemiology of PCP in the recent era of highly active antiretroviral therapy (HAART) is not well known and the impact of HAART on outcome of PCP has been debated.
aimTo determine the epidemiology of PCP in HIV-infected patients and examine the impact of HAART on PCP outcome.
methodsWe performed a retrospective cohort study of 262 patients diagnosed with PCP between January 2000 and December 2003 at a county hospital at an academic medical center. Death while in the hospital was the main outcome measure. Multivariate modeling was performed to determine predictors of mortality.
resultsOverall hospital mortality was 11.6%. Mortality in patients requiring intensive care was 29.0%. The need for mechanical ventilation, development of a pneumothorax, and low serum albumin were independent predictors of increased mortality. One hundred and seven patients received HAART before hospitalization and 16 patients were started on HAART while in the hospital. HAART use either before or during hospitalization was not associated with mortality.
conclusionOverall hospital mortality and mortality predictors are similar to those reported earlier in the HAART era. PCP diagnoses in HAART users likely represented failing HAART regimens or non-compliance with HAART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.